What was in Livtencity’s November 2021 approval letter?
Livtencity (maribavir) received FDA approval in 2021. The “approval letter” issued by the FDA is the document that authorizes the drug’s marketing for its approved indication and typically includes key regulatory terms such as the approved use, labeling requirements, and post-marketing study or reporting obligations (when applicable).
Because an “approval letter” is a specific document, the exact text and date matter for what it states.
When exactly was it approved in 2021 (and what date does the letter reflect)?
The approval letter for Livtencity is tied to the FDA approval date in 2021. If you share whether you mean:
- the FDA “approval letter” posted under Drugs@FDA (with a specific application number), or
- a letter from the manufacturer to clinicians/pharmacies, or
- another regulator in a different country,
I can match the correct letter and pull the relevant details (approved indication, submission info, and any required commitments).
Where can you find the actual November 2021 approval letter?
The most reliable way to locate the exact FDA approval letter is:
- Drugs@FDA (FDA’s database of approval letters and labeling), using the product name and/or application number.
If you tell me the FDA application number (or paste the link/title you’re looking at), I can help interpret what the letter says and summarize the regulatory conditions.
What indication did Livtencity get approved for?
For context around what the approval letter would authorize, Livtencity (maribavir) is used to treat/recover from certain refractory or resistant cytomegalovirus (CMV) situations in transplant patients (the precise wording is set in the approved labeling and reflected in the approval letter).
If you confirm the indication text you see in the letter (or paste it), I can translate it into plain language.
Is the approval letter the same thing as the prescribing information (label)?
No. The approval letter authorizes marketing and lists regulatory conditions. The prescribing information (labeling) is the clinical/usage document that patients and clinicians actually follow. The letter often references the final agreed labeling language.
Quick next step
Reply with either:
1) the link you’re using for the November 2021 approval letter (or the Drugs@FDA entry), or
2) the FDA application number,
and I’ll summarize the letter’s key points (approved use, labeling requirements, and any post-marketing obligations).